ANKE BIO announced that at the 2025 European Society for Medical Oncology Annual Meeting, the company presented the latest research results of its self-developed biological innovative drug HuA21 injection combined with trastuzumab and chemotherapy for the treatment of HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma in the Ib/II phase dose escalation and expansion study. As of February 20, 2025, this study has enrolled 60 HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma first-line patients. According to the assessment by an independent imaging evaluation committee, the objective response rate of the HuA21 group was 80.8%, while the objective response rate of the trastuzumab group was 76.7%, demonstrating good anti-tumor activity. There were no statistically significant differences in the demographic data and baseline characteristics between the two groups of patients
